Physicochemical and In Vitro Evaluation of Drug Delivery of an Antibacterial Synthetic Benzophenone in Biodegradable PLGA Nanoparticles
- 220 Downloads
Due to the increasing incidents of antimicrobial-resistant pathogens, the development of new antibiotics and their efficient formulation for suitable administration is crucial. Currently, one group of promising antimicrobial compounds are the benzophenone tetra-amides which show good activity even against gram-positive, drug-resistant pathogens. These compounds suffer from poor water solubility and bioavailability. It is therefore important to develop dosage forms which can address this disadvantage while also maintaining efficacy and potentially generating long-term exposures to minimize frequent dosing. Biodegradable nanoparticles provide one solution, and we describe here the encapsulation of the experimental benzophenone-based antibiotic, SV7. Poly-lactic-co-glycolic-acid (PLGA) nanoparticles were optimized for their physicochemical properties, their encapsulation efficiency, sustained drug release as well as antimicrobial activity. The optimized formulation contained particles smaller than 200 nm with a slightly negative zeta potential which released 39% of their drug load over 30 days. This formulation maintains the antibacterial activity of SV7 while minimizing the impact on mammalian cells.
KEY WORDSbenzophenone antibiotics PLGA nanoparticles sustained release poorly water-soluble drug
OMM acknowledges the Wayne State University Start-Up grant and Innovation Fellowship grant. SMF acknowledges NIH grant R01AI109139 for support. GC acknowledges UniNa and Compagnia San Paolo in the frame of Programme STAR (CALL 2016). The Electron Microscopy Core Facility at Wayne State University is partially supported by NSF-MRI grant 0216084 and NSF-MRI grant 0922912. We are grateful to Dr. Zhi Mei for expert support with the SEM imaging of our samples.
- 2.Ventola CL. The antibiotic resistance crisis: part 1: causes and threats. P & T : a peer-reviewed journal for formulary management. 2015;40(4):277–83.Google Scholar
- 3.Centers for Diseases Control and Prevention OoID. Antibiotic resistance threats in the United States, 2013. 2013. Available from: https://www.cdc.gov/drugresistance/threat-report-2013/.
- 4.World Health Organization. Worldwide country situation analysis: response to antimicrobial resistance 2015. Available from: http://www.who.int/drugresistance/documents/situationanalysis/en/.
- 14.Organization. WH. Global priority list of antibiotic-resistant bacteria to guide research, discovery, and development of new antibiotics 2017. Available from: http://www.who.int/medicines/publications/WHO-PPL-Short_Summary_25Feb-ET_NM_WHO.pdf?ua=1.
- 19.Lipinski CA. Avoiding investment in doomed drugs, is poor solubility an industry wide problem? Curr Drug Discov. 2001:17–9.Google Scholar
- 20.Company BDa. BBL TM Mueller Hinton II Broth (Cation Adjusted). Rev 12 [Internet]. 2012.Google Scholar
- 21.Institute CaLS. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard. CLSI document M07-A9. Wayne, PA: Clinical and Laboratory Standards Institute; 2012.Google Scholar
- 29.Costabile G, d'Angelo I, Rampioni G, Bondi R, Pompili B, Ascenzioni F, et al. Toward repositioning niclosamide for antivirulence therapy of Pseudomonas aeruginosa lung infections: development of inhalable formulations through nanosuspension technology. Mol Pharm. 2015;12(8):2604–17.CrossRefPubMedGoogle Scholar
- 30.d'Angelo I, Costabile G, Durantie E, Brocca P, Rondelli V, Russo A, et al. Hybrid lipid/polymer nanoparticles for pulmonary delivery of siRNA: development and fate upon in vitro deposition on the human epithelial airway barrier. J Aerosol Med Pulm Drug Deliv. 2018;31(3):170–81.CrossRefPubMedGoogle Scholar